Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0c30afa0e6bf0791861d13cdcee0da7a |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2770-16034 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5256 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10343 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-605 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-86 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-861 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0258 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0002 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-861 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-108 |
filingDate |
2019-08-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0f5c5b0d168597125684573b5c97bb05 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2b36a805aafaca276c968f04cc814bf2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2b176bfc0a921985b90376cee3a2dbc9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9917e785005be4f20ebdf413b672e8ce |
publicationDate |
2020-04-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-2020101149-A1 |
titleOfInvention |
Cellular adjuvants for viral infection |
abstract |
Two-component vaccine formulations and methods are contemplated where the vaccine has an adjuvant component and a therapeutic component. The therapeutic component comprises preferably a recombinant therapeutic virus encoding a therapeutic antigen while the adjuvant component comprises a non-host cell or immune stimulating portion thereof. Notably, use of the adjuvant component will result in significant uptake of the therapeutic component into immune competent cells, even in the absence of receptors for entry of the therapeutic component. In addition, such adjuvant also stimulates expression of the therapeutic antigen. |
priorityDate |
2018-08-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |